Working with an undisclosed startup, EditForce is already using its DNA-binding PPR technology to build more potent engineered T cell therapies for cancer patients. And with a Nagoya-based pharma ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback